Clinical trial · Interventional
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years. Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Hepatic Neoplasms | Liver Neoplasm | ALIAS | 0.90 |
| Neoplasm Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diffusion Weighted MRI scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diffusion Weighted MRI scan
- description
- Patients who are enrolled in the study will undergo an additional diffusion weighted MRI (T2W, DWI and ADC sequences) of the liver.
- interventionNames
- Other: Diffusion Weighted MRI scan
Primary outcomes (1)
- measure
- Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
- timeFrame
- 5 years after last recruit (end of trial)
- description
- Proportion of additional patients diagnosed with liver metastases on DW MRI compared with CT.
Secondary outcomes (5)
- measure
- To compare the baseline risk factors of the primary tumour against the timing and pattern of metastatic disease relapse in the liver.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: 1. Have a high risk primary colorectal malignancy 2. Have a negative CT or includes no confirmatory evidence of liver metastases 3. Is able to undergo treatment if liver metastasis is found 4. Have provided written informed consent to participate in the study 5. Be aged 16 years or over Exclusion Criteria: 1. Have had a previous colorectal malignancy 2. Have metastatic disease 3. Have a synchronous second malignancy 4. Are contraindicated for MRI 5. Has a T3b or below low rectal tumour without EMVI or N1c
References
Publications (0)
Data not yet available